IRVINE, Calif.--(BUSINESS WIRE)--Jan. 23, 2018--
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical
company focused on the discovery, development and commercialization of
first-in-class therapies for the treatment of patients with glaucoma or
ocular hypertension and other diseases of the eye, today announced that
it has commenced a registered underwritten public offering of $75
million of shares of its common stock. The underwriter will have a
30-day option from the date of the offering to purchase up to an
additional $11.25 million of shares of common stock.
Cantor Fitzgerald & Co. is acting as the sole bookrunner for the
Aerie intends to use the net proceeds of the offering for general
corporate purposes, including to fund expansion of its commercialization
programs in North America for both Rhopressa® and Roclatan™,
its clinical and commercialization efforts beyond North America, further
development of other potential pipeline opportunities, including
activities to support the ongoing development of its retina programs and
evaluating possible uses of its existing proprietary portfolio of
molecules beyond ophthalmology, its external business development
efforts, and its manufacturing activities, including the construction of
its own manufacturing plant in Ireland.
A shelf registration statement relating to the shares is effective with
the Securities and Exchange Commission. The shares may be offered only
by means of the prospectus forming a part of the effective registration
statement and a related prospectus supplement. A preliminary prospectus
supplement related to the offering will be filed with the Securities and
Exchange Commission today. An electronic copy of the preliminary
prospectus supplement and the accompanying prospectus will be available
on the website of the Securities and Exchange Commission at www.sec.gov.
Copies of the preliminary prospectus supplement and the final prospectus
supplement, when available, and the accompanying prospectus may be
obtained by contacting Cantor Fitzgerald & Co., Attention: Capital
Markets, 499 Park Ave., 6th Floor, New York, New York 10022, or by
e-mail at email@example.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities of Aerie, and shall not
constitute an offer, solicitation or sale of any security in any state
or jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the securities
laws of any such state or jurisdiction.
About Aerie Pharmaceuticals, Inc.
Aerie is an ophthalmic pharmaceutical company focused on the discovery,
development and commercialization of first-in-class therapies for the
treatment of patients with glaucoma or ocular hypertension and other
diseases of the eye.
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. We may, in some cases, use terms such as “predicts,”
“believes,” “potential,” “proposed,” “continue,” “estimates,”
“anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,”
“will,” “should,” “exploring,” “pursuing” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding our expectations related to the offering discussed
in this press release, including the completion, timing and size of the
offering and the use of proceeds therefrom. By their nature,
forward-looking statements involve risks and uncertainties because they
relate to events and other factors beyond our control. We discuss many
of these risks in greater detail under the heading “Risk Factors” in the
quarterly and annual reports that we file with the Securities and
Exchange Commission (SEC). Any forward-looking statements that we make
in this press release speak only as of the date of this press release.
We assume no obligation to update our forward-looking statements whether
as a result of new information, future events or otherwise, after the
date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20180123006482/en/
Source: Aerie Pharmaceuticals, Inc.
Richard Rubino, 908-947-3540
McClellan, Inc., on behalf of Aerie Pharmaceuticals